Here are the 10-Q quarterly reports from Boston Scientific Corporation (BSX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSX filings page.
Boston Scientific Corporation reported third-quarter and nine-month 2026 results. Third-quarter net sales were $5.138 billion versus $5.065 billion a year earlier; net income was $580 million versus $755 million, and diluted earnings per share were $0.40 versus $0.51. For the nine months ended September 30, 2026, net sales were $15.784 billion versus $14.788 billion and net income was $2.823 billion versus $2.222 billion. A $383 million discrete tax benefit affected nine-month tax results.
The company completed the Nalu Medical and Scivita Medical acquisitions. Its TingSN acquisition is expected to close in the fourth quarter of 2026, subject to customary closing conditions; the Penumbra acquisition is expected to close in early 2027, subject to regulatory clearances and other customary closing conditions, after Penumbra stockholders approved it. Boston Scientific paid MiRus $1.500 billion, exclusive of a prior $100 million payment, for non-voting equity interests and an option to acquire its TAVR business for additional aggregate cash payments totaling $3.000 billion following specified clinical and regulatory milestones.
Nine-month operating cash flow was $2.870 billion versus $3.170 billion. The company repurchased $2.000 billion of common stock; $3.000 billion remained under its repurchase authorization as of September 30, 2026.
Boston Scientific delivered strong first-quarter 2026 results, with net sales of $5.203 billion, up 11.6% from $4.663 billion, driven by double-digit growth in Cardiovascular and MedSurg businesses. Net income attributable to common stockholders rose to $1.341 billion from $674 million, or diluted EPS of $0.90 versus $0.45.
Adjusted diluted EPS was $0.80, up 6.0%. Organic and operational net sales growth were both 9.4%, reflecting innovation and commercial execution, particularly in Electrophysiology and Interventional Cardiology & Vascular Therapies. Cash from operations was $348 million, with higher acquisition spending and capex leading to lower cash balances.
The company continued its acquisition strategy, closing the Nalu Medical deal (total preliminary consideration $588 million), completing the prior Cortex acquisition, signing to buy Scivita Medical and agreeing to acquire Penumbra for about $14.5 billion. It added new revolving credit and term loan facilities to support funding and ended the quarter with total assets of $44.351 billion, senior notes of $10.935 billion and a leverage ratio of 1.87x versus a 4.25x covenant limit.
Boston Scientific reported stronger results for Q3 2025. Net sales rose to $5,065 million from $4,209 million a year ago, lifting gross profit to $3,542 million. Operating income increased to $1,048 million from $733 million, and net income attributable to common stockholders reached $755 million versus $469 million. Diluted EPS was $0.51 compared with $0.32. For the first nine months, net sales were $14,788 million (vs. $12,186 million) and net income was $2,226 million (vs. $1,288 million).
Cash from operations for the nine months rose to $3,170 million from $1,979 million, supporting a series of acquisitions: Bolt Medical ($475 million upfront, up to $200 million future), SoniVie ($362 million upfront, up to $200 million future), Intera Oncology ($172 million), Cortex ($239 million upfront, up to $50 million future), Anrei Medical ($182 million), and another business ($73 million). The company also announced a definitive agreement to acquire Nalu Medical with an upfront cash payment of approximately $533 million upon closing, expected in the first half of 2026, subject to customary conditions.